Avita Medical, a regenerative medicine company specialising in new treatments for wounds and skin defects, has announced the launch of ReGenerCell for chronic wounds and ReNovaCell for repigmentation
The Company now has products configured for three condition areas; burns, chronic wounds (targeted at diabetic foot ulcers and venous leg ulcers), and aesthetic applications (mainly repigmentation and scar revision).
Both ReGenerCell and ReNovaCell products employ regenerative technology first developed for ReCell.
The three presentations of the device enable a clinician to prepare a Regenerative Epithelial Suspension (RES) at the point of care in approximately 30 minutes, using a small sample of the patient’s own skin.
The suspension is then applied to the recipient area to regenerate natural, healthy skin, according to Avita Medical.
ReGenerCell is targeted to help combat chronic wounds, in particular, Diabetic Foot Ulcers (DFUs) and Venous Leg Ulcers (VLUs).
ReNovaCell restores natural pigmentation to the skin where it is absent as a result of vitiligo or damage to the skin.
Avita Medical said that the launch of ReNovaCell provides a clinically proven solution to restore pigmentation in patients where other treatment options have failed. Indications include vitiligo, hyper and hypopigmentation and regenerating damaged skin.
Adam Kelliher, Avita Medical’s UK-based CEO, said: “These new products demonstrate Avita Medical’s commitment to further pioneering the developing field of regenerative medicine, bringing to the market here-and-now solutions that can deliver benefit to patients today.”